Liquidia Technologies Names Robert A. Lippe Chief Operations Officer

Company Sets Stage for Expanded Growth and Operational Excellence

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Liquidia Technologies today announced it has named Robert A. Lippe as the Company's Chief Operations Officer, effective immediately. Mr. Lippe has responsibility for manufacturing research, process development, operations, quality control and compliance and will be a key member of the senior management team.

"Rob's expertise will be a welcome addition to our management team as we continue to leverage our disruptive technology to develop novel and innovative products across several high growth areas of interest."
"Rob brings to Liquidia a proven track record as a biopharmaceutical strategist and a seasoned leader with an impressive breadth of biotechnology operations knowledge and experiences," said Neal Fowler, Chief Executive Officer at Liquidia. "Rob's expertise will be a welcome addition to our management team as we continue to leverage our disruptive technology to develop novel and innovative products across several high growth areas of interest."

Mr. Lippe has more than 25 years of experience in pharmaceutical operations, including bio-pharmaceutical manufacturing and compliance, supply chain, quality assurance and control, business process and operational excellence, facility engineering, and security program implementation.

Prior to joining Liquidia, Mr. Lippe served as an Executive Vice President, Operations & Chief Operations Officer at Alexza Pharmaceuticals where he had operational oversight, including the scale-up and optimization of supply that supported the launch of the company's first commercial product, and advancement of a platform proof-of-concept that enabled acceleration of the company's product pipeline. Before joining Alexza, Mr. Lippe served as the Head of Global Operations & Operational Excellence at Ironwood Pharmaceuticals, Inc., where he was responsible for building and leading the company's worldwide operations division. Prior to Ironwood Pharmaceuticals, Mr. Lippe worked for Genentech, Inc. where he served as the Head of Manufacturing for Genentech's Vacaville Operations after holding multiple positions in strategic operations, drug substance and product manufacturing, and facilities management. Previously, Mr. Lippe spent ten years at Lawrence Livermore National Laboratory and six years as an officer in the U.S. Coast Guard. Mr. Lippe received his MPH and MBA degrees from the University of California, Berkeley, and received a BS degree in marine engineering from the United States Coast Guard Academy.

ABOUT LIQUIDIA TECHNOLOGIES

Liquidia Technologies, founded in 2004, is a privately held biotechnology company located in Research Triangle Park, North Carolina. By leveraging precise fabrication techniques of the semiconductor industry, Liquidia has become the only company in the world with the ability to rapidly design and manufacture precisely engineered particles of virtually any size, shape, or composition using a unique particle engineering and manufacturing platform known as the PRINT® (Particle Replication In Non-Wetting Templates) technology. This unique ability to precisely engineer particles enables scientists to explore new product frontiers that, until now, have been out of reach for the life sciences industry. Liquidia and its partners are currently exploring the application of this novel technology to develop products in several high growth areas such as vaccines, pulmonology, ophthalmology, oral health, and pain. In addition to the development of its own products, Liquidia licenses the PRINT particle technology and its cGMP manufacturing capabilities to support proprietary programs advanced by collaborators. For more information, please go to www.liquidia.com.

Contacts

Liquidia Media Contact:
Michael Parks, 484-356-7105
[email protected]

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.

Vanda Pharmaceuticals is hoping to try again with an amended trial after its experimental skin drug tradipitant failed a phase 3 test.